Comparison of modification of surface xenoantigens on bovine and porcine erythrocytes.
- Author:
Ying-Xia TAN
1
;
Su-Bo LI
;
Jie-Xi WANG
;
Yang-Pei ZHANG
Author Information
1. Department of Blood Biology, Institute of Tranfusion Medicine, Academy of Military Medical Sciences, Beijing 100850, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antigens, Heterophile;
immunology;
Blood Substitutes;
Cattle;
Disaccharides;
immunology;
Epitopes;
immunology;
Erythrocyte Membrane;
immunology;
Erythrocyte Transfusion;
methods;
Erythrocytes;
immunology;
metabolism;
Humans;
Swine;
alpha-Galactosidase;
immunology
- From:
Journal of Experimental Hematology
2005;13(5):878-882
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to explore impact of removal of cell membrane G alalpha1-3Gal beta1-4Glc NAc epitopes (called alpha-Gal) and chemical modification of other xenoantigen on bovine red blood cell (bRBC) and porcine red blood cell (pRBC) antigenicity and to compare their modified erythrocytes, in order to provide basis for development of human blood substitute with rich source, high safety and efficacy. bRBC and pRBC were subjected to both enzymatic removal of membrane alpha-Gal with recombinant coffee bean alpha-galactosidase (rC alpha-GalE) and covalent attachment of benzotriazole carbonate-linked methoxypolyethylene glycol (mPEG-BTC, MW = 20 kD). The effects of treatment were measured by hemagglutination, flow cytometric assay of IgG binding and clinical cross-match testing to human sera. The results showed that although alpha-galactosidase treatment reduced hemagglutination titers to levels similar to negative control, the combination of the treatments was most effective. Clinically used cross-match tests between bRBC, pRBC and human sera demonstrated increased compatibility. Bovine RBC were more robust than pRBC, and had less xenoantigens, and had longer half life than pRBC in vivo. These characteristics suggested that bRBCs were more suitable to investigation as an alternatives to hRBC in clinical transfusion than pRBC. These data suggested that strategies to remove or mask xenoantigens on bRBC reduce antigenicity sufficiently to allow in vitro cross-match compatibility to human sera, and therefore bRBC following modification may be considered as human blood substitute.
